These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 24198891)
1. The impacts of first line highly active antiretroviral therapy on serum selenium, CD4 count and body mass index: a cross sectional and short prospective study. Akinboro AO; Onayemi O; Ayodele OE; Mejiuni AD; Atiba AS Pan Afr Med J; 2013; 15():97. PubMed ID: 24198891 [TBL] [Abstract][Full Text] [Related]
2. Predictive effects of body mass index on immune reconstitution among HIV-infected HAART users in China. Li X; Ding H; Geng W; Liu J; Jiang Y; Xu J; Zhang Z; Shang H BMC Infect Dis; 2019 May; 19(1):373. PubMed ID: 31046702 [TBL] [Abstract][Full Text] [Related]
3. Micronutrient levels and HIV disease status in HIV-infected patients on highly active antiretroviral therapy in the Nutrition for Healthy Living cohort. Jones CY; Tang AM; Forrester JE; Huang J; Hendricks KM; Knox TA; Spiegelman D; Semba RD; Woods MN J Acquir Immune Defic Syndr; 2006 Dec; 43(4):475-82. PubMed ID: 17019373 [TBL] [Abstract][Full Text] [Related]
4. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235 [TBL] [Abstract][Full Text] [Related]
5. Influence of highly active antiretroviral therapy on micronutrient profiles in HIV-infected patients. Rousseau MC; Molines C; Moreau J; Delmont J Ann Nutr Metab; 2000; 44(5-6):212-6. PubMed ID: 11146326 [TBL] [Abstract][Full Text] [Related]
6. Prevalence and determinants of glucose intolerance among HIV/AIDS patients in north-central Nigeria. Reng SR; Uloko EA; Puepet HF; Onwuegbuzie AG; Ramalan AM Niger J Med; 2016; 25(2):128-32. PubMed ID: 29944309 [TBL] [Abstract][Full Text] [Related]
7. Association of Body Composition and Other Clinical Factors with Incomplete Immune Response after Highly Active Antiretroviral Therapy. Sun PT; Yu W; Li TS; Lin Q; Guo FP; Zhou XH; Du GY; Xu Y; Guan WM Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):459-464. PubMed ID: 28877821 [TBL] [Abstract][Full Text] [Related]
8. The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience. Erhabor O; Ejele OA; Nwauche CA Niger J Clin Pract; 2006 Dec; 9(2):128-33. PubMed ID: 17319344 [TBL] [Abstract][Full Text] [Related]
9. Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients. Tedaldi EM; Brooks JT; Weidle PJ; Richardson JT; Baker RK; Buchacz K; Moorman AC; Wood KC; Holmberg SD; J Acquir Immune Defic Syndr; 2006 Sep; 43(1):35-41. PubMed ID: 16885779 [TBL] [Abstract][Full Text] [Related]
10. Smear positive pulmonary tuberculosis among HIV patients receiving highly active antiretroviral therapy in Dar es Salaam, Tanzania. Bwana V; Tenu F; Magesa SM; Mfinanga SG Tanzan J Health Res; 2011 Jan; 13(1):14-20. PubMed ID: 24409642 [TBL] [Abstract][Full Text] [Related]
11. Risks of cardio-vascular diseases among highly active antiretroviral therapy (HAART) treated HIV seropositive volunteers at a treatment centre in Lagos, Nigeria. Ekun OA; Fasela EO; Oladele DA; Liboro GO; Raheem TY Pan Afr Med J; 2021; 38():206. PubMed ID: 33995812 [TBL] [Abstract][Full Text] [Related]
12. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy. Wong KH; Chan KC; Lee SS Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819 [TBL] [Abstract][Full Text] [Related]
13. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254 [TBL] [Abstract][Full Text] [Related]
14. Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. Kyeyune R; Saathoff E; Ezeamama AE; Löscher T; Fawzi W; Guwatudde D BMC Infect Dis; 2014 Sep; 14():496. PubMed ID: 25209550 [TBL] [Abstract][Full Text] [Related]
15. Relationship between Body Mass Index and Mortality in HIV-Infected HAART Users in the Women's Interagency HIV Study. Sharma A; Hoover DR; Shi Q; Gustafson D; Plankey MW; Hershow RC; Tien PC; Golub ET; Anastos K PLoS One; 2015; 10(12):e0143740. PubMed ID: 26699870 [TBL] [Abstract][Full Text] [Related]
16. The predictive role of CD4 Li CX; Li YY; He LP; Kou J; Bai JS; Liu J; Tian B; Cao LJ; Wang KH; Kuang YQ BMC Immunol; 2019 Aug; 20(1):31. PubMed ID: 31455209 [TBL] [Abstract][Full Text] [Related]
17. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients. Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298 [TBL] [Abstract][Full Text] [Related]
18. Vitamin-D deficiency impairs CD4+T-cell count recovery rate in HIV-positive adults on highly active antiretroviral therapy: A longitudinal study. Ezeamama AE; Guwatudde D; Wang M; Bagenda D; Kyeyune R; Sudfeld C; Manabe YC; Fawzi WW Clin Nutr; 2016 Oct; 35(5):1110-7. PubMed ID: 26371397 [TBL] [Abstract][Full Text] [Related]
19. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741 [TBL] [Abstract][Full Text] [Related]
20. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]